Curaleaf Leads Cannabis Rally Into Q3 Print

Curaleaf Holdings heads into its November 5 Q3 results riding the sharpest weekly move in its peer group, up 19% over the past week and 11% on Monday alone, raising the question of whether the stock has run ahead of what the numbers can justify.

The price surge dominates the positioning picture. Short interest is minimal at just 0.6% of the free float, so there is no meaningful short-covering dynamic driving the rally. The borrow market reflects that: availability is wide, with roughly six shares available to borrow for every one already lent out, and cost to borrow at 3.8% is modest and drifting lower on the week. The lending market is not telling a squeeze story. What is notable is that short shares outstanding have jumped roughly 89% over the past month, though from a very low base, suggesting some traders began building cautious positions even as the stock drifted sideways before this week's acceleration.

The rally is not unique to Curaleaf, but the magnitude stands out. Cannabis peers also moved higher on the day: GTII added 5%, TRLV gained 4%, and WEED rose 4%. Curaleaf's 11% session gain was roughly double the peer average, which hints at stock-specific re-rating rather than a pure sector lift. The EV/EBITDA multiple has expanded materially, moving from around 10.6 to 11.2 over the past month. The company is loss-making on a reported basis, with a negative price-to-earnings ratio, so the valuation debate sits squarely around EBITDA and cash generation.

Institutional ownership adds an interesting layer. AdvisorShares added over 14 million shares in the most recent reported period, taking its stake to 4.7% of shares outstanding, nearly matching chairman Boris Jordan's 4.8% holding. The timing of that build, arriving ahead of the earnings date, makes it one of the more watched positions going into the print. Insider activity has been less constructive: the net insider position over the past 90 days shows modest net selling, primarily from Peter Clateman, though transaction sizes were small and trade significance scores were low.

The 30-day EPS momentum factor ranking at the 89th percentile suggests analysts have been lifting near-term estimates into the event. EPS surprise history, however, sits at only the 8th percentile, meaning the company has a track record of falling short of consensus. That divergence, rising estimates meeting a history of disappointment, is what the November 5 print will put to the test.